#138 – You CAN Go Home Again: A review of OPAT and CoPAT from the MAD-ID/SIDP Annual Meeting

#138 – You CAN Go Home Again: A review of OPAT and CoPAT from the MAD-ID/SIDP Annual Meeting

Author: Society of Infectious Diseases Pharmacists July 3, 2026 Duration: 1:14:53

In this must-listen episode, Dr. Ryan Moenster is joined by Dr. Monica Mahoney and Dr. Mark Gilchrist to dive deep into the evolving landscape of outpatient parenteral antimicrobial therapy (OPAT) and complex outpatient antimicrobial therapy (CoPAT), highlighting real-world challenges, patient selection, and emerging treatment strategies. Navigating outpatient antimicrobial management can be complex, but this episode breaks down key insights and practical applications to help clinicians optimize care beyond the hospital.

References:

1.       Noble AL, Patel S, Birnie E, et al. 2026 updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK. JAC Antimicrob Resist. 2026;8(2).

2.       British Society for Antimicrobial Chemotherapy (BSAC). OPAT Global Summit 2027.

3.       Naicker S, Roberts JA, Cheng V, et al. A review of antimicrobial stability testing guidance for outpatient parenteral antimicrobial therapy programmes: Is it time for global harmonization of testing frameworks? JAC Antimicrob Resist. 2024;6(6).

4.       Gilchrist M, Jamieson C, Drummond F, et al. Assessment of ceftolozane/tazobactam degradation profile and toxicity data in elastomeric devices for continuous infusion via outpatient parenteral antimicrobial therapy (OPAT). JAC Antimicrob Resist. 2023;5(2).

5.       Naicker S, Roberts JA, Won H, et al. Evaluation of the stability of ceftazidime/avibactam in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy utilizing a national stability protocol framework. JAC Antimicrob Resist. 2024;6(2).

6.       Wolie ZT, Unwin S, Burke A, et al. Evaluation of the stability of tigecycline in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy. JAC Antimicrob Resist. 2025;7(3).

7.       Solomon DA, Beieler AM, Levy S, et al. Perspectives on the use of outpatient parenteral antibiotic therapy for people who inject drugs: Results from an online survey of infectious diseases clinicians. Open Forum Infect Dis. 2023;10(7):ofad372. doi:10.1093/ofid/ofad372.

8.       Yagnik KJ, Brown LS, Saad HA, et al. Implementation of IV push antibiotics for outpatients during a national fluid shortage following Hurricane Maria. Open Forum Infect Dis. 2022;9(5):ofac117. doi:10.1093/ofid/ofac117.

9.       Boettcher SR, Kenney RM, Everson NA, et al. Discharge delays and costs associated with outpatient parenteral antimicrobial therapy for multidrug-resistant organisms: A retrospective cohort study. Open Forum Infect Dis. 2025;13(1):ofaf770.

10.   Rivera CG, Mara KC, Mahoney MV, Ryan KL. Survey of pharmacists on their roles and perceptions of outpatient parenteral antimicrobial therapy in the United States. Antimicrob Steward Healthc Epidemiol. 2022;2(1):e69.

11.   Rapoport AB, Fischer LS, Santibanez S, et al. Infectious diseases physicians’ perspectives regarding injection drug use and related infections—United States, 2017. Open Forum Infect Dis. 2018;5(7):ofy132. doi:10.1093/ofid/ofy132.

12.   Turner NA, Hamasaki T, Doernberg SB, et al.; Antibacterial Resistance Leadership Group. Dalbavancin for treatment of Staphylococcus aureus bacteremia: The DOTS randomized clinical trial. JAMA. 2025;334(10):866–877. doi:10.1001/jama.2025.12543.

13.   Volk CF, Hutson PR, Rose WE. Simulated target attainment of multidose regimens of dalbavancin for prolonged durations of therapy. Open Forum Infect Dis. 2024;11(6):ofae315. doi:10.1093/ofid/ofae315.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About

Instagram: @SIDPharm ( https://www.instagram.com/sidpharm/) or @breakpointspodcast_sidp (https://www.instagram.com/breakpointspodcast_sidp/) https://www.instagram.com/breakpointspodcast_sidp/?hl=en

Facebook: https://www.facebook.com/sidprx

LinkedIn:  https://www.linkedin.com/company/sidp/

SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/


Hosted by the Society of Infectious Diseases Pharmacists, Breakpoints is a podcast dedicated to the intricate and ever-evolving world of antimicrobial therapy. Each episode delves into the practical challenges and scientific nuances faced by pharmacists on the front lines of patient care, from interpreting susceptibility data and optimizing dosing strategies to navigating the complexities of antimicrobial stewardship. The conversations in this podcast bridge the gap between groundbreaking infectious diseases research and its direct application in clinical settings, offering insights that are both academically rigorous and immediately useful. You’ll hear expert discussions on new resistance patterns, evolving treatment guidelines, and the real-world implementation of life-saving protocols. Designed for healthcare professionals committed to precision medicine, Breakpoints provides a deeper understanding of how to effectively manage infections and improve patient outcomes. Tune in for thoughtful analysis and forward-thinking dialogue that defines the critical role of specialized pharmacists in public health.
Author: Language: en-us Episodes: 50

Breakpoints
Podcast Episodes
#121 – Finding BALANCE in Antibiotic Durations: The BALANCE Trial [not-audio_url] [/not-audio_url]

Duration: 1:09:41
In this second-ever collaboration between SIDP’s Breakpoints and ESCMID’s Communicable podcasts, hosts Erin McCreary and Angela Huttner invite the two principal investigators and visionaries who spearheaded the Bacteremi…
#120 – What’s Pneu in Community-Acquired Pneumonia [not-audio_url] [/not-audio_url]

Duration: 1:06:21
Drs. Whitney Hartlage (@whithartlage11) and Sam Windham join Dr. Ryan Moenster to discuss updates in the diagnosis and management of community-acquire pneumonia. Hear from our guests on the role of rapid diagnostic tests…
#119 – Dosing Consult: Fluconazole [not-audio_url] [/not-audio_url]

Duration: 51:23
Drs. David Andes and Isabel Spriet join Dr. Jeannette Bouchard to discuss all of the top questions our audience had on fluconazole dosing. Who needs a load? How much fluconazole is too much fluconazole? And what did one…
#115 – Silver Lining of Shortages: Blood Culture Best Practices [not-audio_url] [/not-audio_url]

Duration: 1:05:34
Dr. Jeannette Bouchard is joined by experts Dr. Romney Humphries, Emily Fox, and Matt Miller to discuss the hot topic of blood culture stewardship and the details of how these experts persevered through the recent blood…
#114 – Dosing Consult: Amoxicillin/Clavulanate [not-audio_url] [/not-audio_url]

Duration: 1:10:13
Drs. Pier Giorgio Cojutti and Navaneeth Narayanan join Dr. Megan Klatt to break down what you need to know about amoxicillin/clavulanate dosing. Tune in to learn more about the PK/PD of amoxicillin and clavulanic acid, h…
#113 – Ask ChatGPT: The Role of AI in Healthcare [not-audio_url] [/not-audio_url]

Duration: 56:33
Dr. Brent Richards joins Dr. Erin McCreary to discuss the growing capability for artificial intelligence (AI) and big data in the healthcare industry. What is AI and machine learning, how can these tools enhance patient…
#112 – Say It Ain't Steno: Stenotrophomonas maltophilia Review [not-audio_url] [/not-audio_url]

Duration: 1:12:10
Drs. Amy Mathers and Julie Ann Justo join Dr. Erin McCreary to talk all things Stenotrophomonas maltophilia, a water-loving organism and frequent colonizer. Hear from the experts on why this organism is so difficult to t…